Navigation Links
OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
Date:7/14/2008

cers and other members of management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Sonus, including their respective security holdings, is set forth in Sonus' Amendment # 1 to Form 10-K for the fiscal year ended December 31, 2007, filed with the Securities and Exchange Commission on April 29, 2008, and the Proxy Statement filed with the SEC on July 3, 2008. As of June 30, 2008, OncoGenex' directors and executive officers beneficially owned approximately 1,755,000 shares, or 14.5%, of OncoGenex' capital stock. Investors may obtain additional information regarding the interests of OncoGenex, Sonus and their respective executive officers and directors in the merger by reading the Proxy Statement for such proposed transaction.

The Proxy Statement and other relevant materials, and any other documents filed by Sonus with the SEC, may be obtained free of charge at the SEC's web site at http://www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Sonus by directing a request to: Sonus Pharmaceuticals, Inc., 1522 217th Place SE, Suite 100, Bothell, WA 98021, Phone (425) 686-1500, Fax (425) 686-1600, Attention: Investor Relations.

CONTACT: OncoGenex Media and Investor Contact: Jason I. Spark, Porter Novelli Life Sciences, (619) 849-6005, jspark@pnlifesciences.com


'/>"/>
SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex increases economic interest in lead cancer drug OGX-011
2. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
9. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Bill Jacobs Automotive, a group of car dealerships ... with the Heartland Blood Center and offering free oil change ... takes place Saturday, Jan. 18 at the Bill Jacobs Cadillac ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... Sept. 25 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: ... on researching,developing, manufacturing and marketing biopharmaceutical products,primarily ... filed with the Chinese,State Food and Drug ... IU,dosage formulation of EPIAO for the treatment ...
... of Business ... Development Activities -, LA JOLLA, Calif., Sept. ... it will transition from a,discovery and development company to a development-only ... will,streamline operations through the shut down of its discovery operations,and seek ...
... Cells and Other ... Development Programs, ROCKVILLE, Md., ... immunotherapeutics to treat,autoimmune disorders, cancer and infectious diseases, today announced that,it ... led by,Nextech Venture, included additional new investors Arcus Ventures, Innovis,Investments and ...
Cached Biology Technology:3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 23SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 3TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 2TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 3TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 4MacroGenics Raises $25M in Series D-2 Financing 2MacroGenics Raises $25M in Series D-2 Financing 3MacroGenics Raises $25M in Series D-2 Financing 4
(Date:7/9/2014)... one of the amphibians with the highest distribution in ... of water where it comes into contact with the ... carried out by the Spaniard Germn Orizaola from the ... these frogs have developed a defensive response to the ... bodies if they co-exist with the crayfish. , Numerous ...
(Date:7/9/2014)... function and increase the survival rate of naturally ... School of Pharmaceutical Sciences, Southwest University, China performed ... administered with low dose of levothyroxine for 3 ... exhibited an obvious improvement in cognitive and an ... The underlying mechanism was demonstrated that levothyroxine treatment ...
(Date:7/9/2014)... vitamin D in their blood are more likely to survive ... highest levels of vitamin D have half the risk of ... reveal. , The study is the first to correlate total ... their diagnosis which includes that produced after exposure to ... long term survival prospects. , The University of Edinburgh ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
... Traffic accidents involving wildlife are on the rise in Europe. ... be useful for increasing safety and preventing human and animal ... researchers have established at what time, on what day of ... roe deer are most likely to take place. Car ...
... that cancerous tumors grow collections of abnormal blood cells, the ... new evidence in an animal model suggests that blood vessels ... same purposeand could provide the key to a new way ... L. Makey, Edmund Chinchar, Carissa Howie, and Lucio Miele, all ...
... Animal sanctuaries can play an important role in rehabilitating goats ... scientists at Queen Mary, University of London. In ... moods in 18 goats, nine of which had endured poor ... shelter before arriving at a sanctuary. They created a spatial ...
Cached Biology News:Roe deer more likely to be run over at nightfall on a Sunday in April 2Drug reduces fat by blocking blood vessels 2Drug reduces fat by blocking blood vessels 3Rescue me: New study finds animals do recover from neglect 2
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
POU domain, class 2, transcription factor 2,...
HSPBP1 Antibody...
golgi reassembly stacking protein 2, 55kDa...
Biology Products: